

**Faculty Listing for Tufts CSDD 39<sup>th</sup> Annual Postgraduate Course in Clinical Pharmacology Drug Development, and Regulation****Kenneth I Kaitin, PhD**

*Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine*

**Richard I. Shader, MD**

*Professor Emeritus, Molecular Physiology and Pharmacology, Tufts University School of Medicine*

**Paul R. Beninger, MD, MBA**

*Vice-President, Global Patient Safety, Genzyme Corporation*

**Paul A. Bleicher, MD, PhD**

*Chief Medical Officer, Humedica, Inc.*

**Helen W. Boucher, MD**

*Director, Infectious Diseases Fellowship Program, Associate Professor of Medicine, Division of Geographic Medicine & Infectious Diseases, TMC*

**Robert F. Butz, PhD****Jerry M. Collins, PhD**

*Associate Director for Developmental Therapeutics, Division of Cancer Treatment and Diagnosis, NCI, NIH*

**Michael H. Court, BVSc, PhD**

*Associate Professor, Dept. of Molecular Physiology and Pharmacology, Tufts University School of Medicine*

**Stephen H. Curry, PhD, DSc (Med.)**

*President, Stephen H. Curry Consulting*

**Janet Forrester, PhD**

*Associate Professor, Department of Public Health & Community Medicine, Tufts University School of Medicine*

**Kenneth A. Getz, MBA**

*Senior Research Fellow, Tufts Center for the Study of Drug Development, Tufts University*

**Alberto Grignolo, PhD**

*Corporate V.P., Global Strategy and Services, PAREXEL Consulting*

**Laurie A. Halloran, BSN, MS**

*President & CEO, Halloran Consulting Group, Inc.*

**Judith K. Jones, MD, PhD**

*President & CEO, The Degge Group, Ltd.*

**Sandra L. Kweder, MD**

*Deputy Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S.*

**Peter J. Neumann, ScD**

*Director, Center for the Evaluation of Value & Risk in Health, Institute for Clinical Research & Health Policy Studies, TMC*

**Randel E. Richner, BSN, MPH**

*Founder and President, Neocure Group*

**Michele K. Russell-Einhorn, JD**

*Senior Director, Office for Human Research Studies, Dana-Farber Cancer Institute*

**William K. Sietsema, PhD**

*Vice President, US Regulatory Consulting and Submissions, INC Research*

**Alison Taunton-Rigby, PhD, OBE**

*Director & Trustee, Healthcare, Life Sciences and Financial Services*

**John Urquhart, MD, FRCPE, FRSE**

*Emeritus Professor, Pharmaco-epidemiology, Maastricht University*

**Priscilla Velentgas, PhD**

*Director of Epidemiology at Outcome Sciences, Inc.*